{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:02:29Z","timestamp":1777723349629,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00108-024-01731-1","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T14:02:16Z","timestamp":1718373736000},"page":"681-689","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Endokrine Nebenwirkungen von Tumortherapien","Endocrine side effects of tumor treatment"],"prefix":"10.1007","volume":"65","author":[{"given":"Johanna","family":"Braegelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"3","key":"1731_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1124\/jpet.105.084145","volume":"315","author":"A Arora","year":"2005","unstructured":"Arora\u00a0A, Scholar\u00a0EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J\u00a0Pharmacol Exp Ther 315(3):971\u2013979. https:\/\/doi.org\/10.1124\/jpet.105.084145","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1731_CR2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1007\/s12020-020-02355-9","volume":"69","author":"X Bai","year":"2020","unstructured":"Bai\u00a0X, Lin\u00a0X, Zheng\u00a0K, Chen\u00a0X, Wu\u00a0X, Huang\u00a0Y, Zhuang\u00a0Y (2020) Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a\u00a0disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine 69(3):670\u2013681. https:\/\/doi.org\/10.1007\/s12020-020-02355-9","journal-title":"Endocrine"},{"issue":"1","key":"1731_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.17925\/EE.2020.16.1.32","volume":"16","author":"S Bhattacharya","year":"2020","unstructured":"Bhattacharya\u00a0S, Goyal\u00a0A, Kaur\u00a0P, Singh\u00a0R, Kalra\u00a0S (2020) Anticancer drug-induced thyroid dysfunction. Eur Endocrinol 16(1):32\u201339. https:\/\/doi.org\/10.17925\/EE.2020.16.1.32","journal-title":"Eur Endocrinol"},{"key":"1731_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710","author":"SR Bornstein","year":"2016","unstructured":"Bornstein\u00a0SR, Allolio\u00a0B, Arlt\u00a0W, Barthel\u00a0A, Don-Wauchope\u00a0A, Hammer\u00a0GD, Husebye\u00a0ES, Merke\u00a0DP, Murad\u00a0MH, Stratakis\u00a0CA, Torpy\u00a0DJ (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J\u00a0Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2015-1710","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"1731_CR5","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1200\/JCO.2017.76.3268","volume":"36","author":"W Chemaitilly","year":"2018","unstructured":"Chemaitilly\u00a0W, Cohen\u00a0LE, Mostoufi-Moab\u00a0S, Patterson\u00a0BC, Simmons\u00a0JH, Meacham\u00a0LR, van Santen\u00a0HM, Sklar\u00a0CA (2018) Endocrine late effects in childhood cancer survivors. J\u00a0Clin Oncol 36(21):2153\u20132159. https:\/\/doi.org\/10.1200\/JCO.2017.76.3268","journal-title":"J Clin Oncol"},{"issue":"1","key":"1731_CR6","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.currproblcancer.2021.100776","volume":"46","author":"YM Cheung","year":"2022","unstructured":"Cheung\u00a0YM, McDonnell\u00a0M, Hamnvik\u00a0OR (2022) A\u00a0targeted approach to phosphoinositide-3-kinase\/Akt\/mammalian target of rapamycin-induced hyperglycemia. Curr Probl Cancer 46(1):100776. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100776","journal-title":"Curr Probl Cancer"},{"issue":"2","key":"1731_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.tem.2021.10.009","volume":"33","author":"S Chiloiro","year":"2022","unstructured":"Chiloiro\u00a0S, Bianchi\u00a0A, Giampietro\u00a0A, Milardi\u00a0D, De Marinis\u00a0L, Pontecorvi\u00a0A (2022) The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. Trends Endocrinol Metab 33(2):87\u2013104. https:\/\/doi.org\/10.1016\/j.tem.2021.10.009","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1731_CR8","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"S Cook","year":"2024","unstructured":"Cook\u00a0S, Samuel\u00a0V, Meyers\u00a0DE, Stukalin\u00a0I, Litt\u00a0I, Sangha\u00a0R, Morris\u00a0DG, Heng\u00a0DYC, Pabani\u00a0A, Dean\u00a0M, Navani\u00a0V (2024) Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open 7(1):e2352302. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52302","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1731_CR9","doi-asserted-by":"publisher","first-page":"2204754","DOI":"10.1080\/2162402X.2023.2204754","volume":"12","author":"A Daban","year":"2023","unstructured":"Daban\u00a0A, Gonnin\u00a0C, Phan\u00a0L, Saldmann\u00a0A, Granier\u00a0C, Lillo-Lelouet\u00a0A, Le Beller\u00a0C, Pouchot\u00a0J, Weiss\u00a0L, Tartour\u00a0E, Fabre\u00a0E, Medioni\u00a0J, Oudard\u00a0S, Vano\u00a0YA, Dragon-Durey\u00a0MA, Simonaggio\u00a0A (2023) Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs). OncoImmunology 12(1):2204754. https:\/\/doi.org\/10.1080\/2162402X.2023.2204754","journal-title":"OncoImmunology"},{"issue":"7","key":"1731_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ejca.2012.01.036","volume":"48","author":"S Feldt","year":"2012","unstructured":"Feldt\u00a0S, Sch\u00fcssel\u00a0K, Quinzler\u00a0R, Franzmann\u00a0A, Czeche\u00a0S, Ludwig\u00a0W\u2011D, Schulz\u00a0M (2012) Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a\u00a0cohort study. Eur J Cancer 48(7):974\u2013981. https:\/\/doi.org\/10.1016\/j.ejca.2012.01.036","journal-title":"Eur J Cancer"},{"issue":"11","key":"1731_CR11","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","volume":"21","author":"JW Goldman","year":"2016","unstructured":"Goldman\u00a0JW, Mendenhall\u00a0MA, Rettinger\u00a0SR (2016) Hyperglycemia associated with targeted oncologic treatment: mechanisms and management. Oncologist 21(11):1326\u20131336. https:\/\/doi.org\/10.1634\/theoncologist.2015-0519","journal-title":"Oncologist"},{"issue":"5","key":"1731_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals\u00a0P, Cameron\u00a0S, Cipolletta\u00a0D, Cremasco\u00a0V, Crystal\u00a0A, Hewes\u00a0B, Mueller\u00a0B, Quaratino\u00a0S, Sabatos-Peyton\u00a0C, Petruzzelli\u00a0L, Engelman\u00a0JA, Dranoff\u00a0G (2017) Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer 17(5):286\u2013301. https:\/\/doi.org\/10.1038\/nrc.2017.17","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1731_CR13","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","volume":"2","author":"A Haslam","year":"2019","unstructured":"Haslam\u00a0A, Prasad\u00a0V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2535","journal-title":"JAMA Netw Open"},{"key":"1731_CR14","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini\u00a0S, Chehade\u00a0R, Boldt\u00a0RG, Raphael\u00a0J, Blanchette\u00a0P, Maleki Vareki\u00a0S, Fernandes\u00a0R (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2014a systematic review and meta-analysis. Cancer Treat Rev 92:102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134","journal-title":"Cancer Treat Rev"},{"key":"1731_CR15","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-22-0689","author":"ES Husebye","year":"2022","unstructured":"Husebye\u00a0ES, Castinetti\u00a0F, Criseno\u00a0S, Curigliano\u00a0G, Decallonne\u00a0B, Fleseriu\u00a0M, Higham\u00a0CE, Lupi\u00a0I, Paschou\u00a0SA, Toth\u00a0M, van der Kooij\u00a0M, Dekkers\u00a0OM (2022) Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"key":"1731_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000591","author":"A Kotwal","year":"2019","unstructured":"Kotwal\u00a0A, Haddox\u00a0C, Block\u00a0M, Kudva\u00a0YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. https:\/\/doi.org\/10.1136\/bmjdrc-2018-000591","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1731_CR17","doi-asserted-by":"publisher","year":"2023","unstructured":"Krebs in Deutschland f\u00fcr 2019\/2020, https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/krebs_in_deutschland_2023.pdf?__blob=publicationFile,  https:\/\/doi.org\/10.25646\/11357 (2023).","DOI":"10.25646\/11357"},{"issue":"5","key":"1731_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrclinonc.2017.56","volume":"14","author":"M Lin","year":"2017","unstructured":"Lin\u00a0M, Jin\u00a0J (2017) Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis. Nat Rev Clin Oncol 14(5):268\u2013268. https:\/\/doi.org\/10.1038\/nrclinonc.2017.56","journal-title":"Nat Rev Clin Oncol"},{"key":"1731_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3238\/arztebl.m2021.0143","volume":"118","author":"K Mai","year":"2021","unstructured":"Mai\u00a0K, Fassnacht\u00a0M, F\u00fchrer-Sakel\u00a0D, Honegger\u00a0JB, Weber\u00a0MM, Kroiss\u00a0M (2021) The diagnosis and management of endocrine side effects of immune checkpoint inhibitors. Dtsch \u00c4rztebl Int 118:389\u2013396. https:\/\/doi.org\/10.3238\/arztebl.m2021.0143","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"11","key":"1731_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner\u00a0TD, Coleman\u00a0R, Hadji\u00a0P, Hofbauer\u00a0LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6(11):901\u2013910. https:\/\/doi.org\/10.1016\/S2213-8587(18)30047-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1731_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","volume":"6","author":"F Torino","year":"2009","unstructured":"Torino\u00a0F, Corsello\u00a0SM, Longo\u00a0R, Barnabei\u00a0A, Gasparini\u00a0G (2009) Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 6(4):219\u2013228. https:\/\/doi.org\/10.1038\/nrclinonc.2009.4","journal-title":"Nat Rev Clin Oncol"},{"key":"1731_CR22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad670","author":"I Vardarli","year":"2023","unstructured":"Vardarli\u00a0I, Tan\u00a0S, Brandenburg\u00a0T, Weidemann\u00a0F, G\u00f6rges\u00a0R, Herrmann\u00a0K, F\u00fchrer\u00a0D (2023) Risk and incidence of endocrine immune-related adverse effects under checkpoint inhibitor mono- or combination therapy in solid tumors: a\u00a0meta-analysis of randomized controlled trials. J\u00a0Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad670","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1731_CR23","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1530\/EJE-13-0586","volume":"170","author":"B Verg\u00e8s","year":"2014","unstructured":"Verg\u00e8s\u00a0B, Walter\u00a0T, Cariou\u00a0B (2014) Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 170(2):R43\u201355. https:\/\/doi.org\/10.1530\/EJE-13-0586","journal-title":"Eur J Endocrinol"},{"key":"1731_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","author":"JJ Wright","year":"2021","unstructured":"Wright\u00a0JJ, Powers\u00a0AC, Johnson\u00a0DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1731_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong\u00a0L, Li\u00a0Y, Xiong\u00a0L, Wang\u00a0W, Wu\u00a0M, Yuan\u00a0T, Yang\u00a0W, Tian\u00a0C, Miao\u00a0Z, Wang\u00a0T, Yang\u00a0S (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Sig Transduct Target Ther 6(1):201. https:\/\/doi.org\/10.1038\/s41392-021-00572-w","journal-title":"Sig Transduct Target Ther"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01731-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01731-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01731-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T07:03:24Z","timestamp":1719385404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01731-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1731"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01731-1","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"23 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Braegelmann gibt an, dass kein Interessenkonflikt besteht. D.\u00a0F\u00fchrer hat Honorare f\u00fcr Referenten\u2011\/Beratert\u00e4tigkeit von Eli Lilly, Ipsen, Eisai, Roche, Novartis und MedUpdate erhalten. S.\u00a0Tan hat Honorare f\u00fcr Referenten\u2011\/Beratert\u00e4tigkeit und Forschungsf\u00f6rderung erhalten von Abbott, ApoScience, Bayer, Berlin-Chemie, Boehringer Ingelheim, Dexcom, Eli Lilly, Merck Serono, Novo Nordisk, Sanofi Aventis, SinoCare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}